CCRM Australia is seeking Expressions of Interest from Australian academic researchers with an interest in Type 1 Diabetes to participate in an emerging international collaboration focused on accelerating scalable cell and gene therapies.

This initiative is being developed in partnership with CCRM (Centre for Commercialization of Regenerative Medicine) in Canada. The collaboration will bring together leading academic, clinical and industry groups to address key challenges in translating next-generation therapies into clinically viable and manufacturable solutions.

The focus is on iPSC-derived beta cell therapies, with an emphasis on clinically relevant and scalable pathways. The program aims to address key bottlenecks in reproducibility, process development and clinical implementation.

Areas of interest include:

• Cell source development and biomanufacturing

• Beta cell differentiation and function

• Cell survival and engraftment

• Immune protection and cell shielding technologies

• Translational and clinical research in Type 1 Diabetes

• Enabling platforms and analytical technologies

This is an opportunity to contribute to a globally connected effort and help shape how these therapies advance through translation, manufacturing and into the clinic.

To express interest or discuss alignment, please contact:

• Silvio Tiziani: silvio.tiziani@ccrmaustralia.com.au

• Chih Wei Teng: Chihwei.Teng@ccrmaustralia.com.au